Details of the Drug Reposition

General Information of This Drug (ID: DM6CWSO)

Drug Name
Defibrotide   DM6CWSO
Synonyms Defitelio; Defibrotide (iv, veno-occlusive disease); Defibrotide (iv, veno-occlusive disease), Gentium

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Plasma cell myeloma DIS0DFZ0 2A83.1 Approved [1]
Hepatic veno-occlusive disease DISAIU45 DB98.6 Approved [2]
------------------------------------------------------------------------------------
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Diabetic nephropathy DIS2FCCT GB61.Z Phase 3 [3]
------------------------------------------------------------------------------------
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Coronavirus Disease 2019 (COVID-19) DISM7GNX 1D6Y Phase 2 [4]
------------------------------------------------------------------------------------

References

1 Defibrotide FDA Label
2 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 208114
3 ClinicalTrials.gov (NCT00358501) Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients. U.S. National Institutes of Health.
4 ClinicalTrials.gov (NCT04335201) Defibrotide in COVID-19 Pneumonia. U.S. National Institutes of Health.